Abstract
Background: A tumor system not only consists of diverse cell types but also comprises all components of action insofar that these components are oriented in terms of diverse cell types. Methods: Thus, it is necessary to decode paradox situations of cellular rationalization, deformation, and communication processes or, in other words, to uncover inconsistencies within tumor cell compartments or distinct topologies of aggregated action effects. Here, a theory may be helpful that discharges into an action-theoretical abstraction and simultaneously includes evolutionary tumor developments. In an evolutionary process, tumor cells may exploit the whole extent of the rationalization features of stroma cells to implement the functional diversity of systems behavior aimed at maintaining homeostasis, and robustness in tumor systems. The introduction of genomic/non-genomic systems-directed therapeutic approaches may allow both, the uncovering of systems topologies of aggregated action effects and the broadening of therapeutic options via systems-directed approaches. Results: (1) Tumor systems biology is now turning into a scientific co-subject. (2) Developing actiontheoretical systems terms with the corresponding conceptual equipment may contribute to the classification of tumor subsystems. (3) Systems-directed therapies may meet new therapeutic requirements, which might help to create therapeutic approaches that are specifically designed for the demand of tumor stages, corresponding systems stages. Conclusions: Therefore, patients would probably not have to be selected according to age and/or co-morbidities because of known adverse toxicities of standard therapies (maximal tolerable doses). In contrast, therapies may meet the (individual) tumor systems characteristics by a systems-orientated selection of biomodulatory acting agents. As shown, toxicities may be modest.
Keywords: Tumor systems biology, systems assessment tools
Current Cancer Therapy Reviews
Title: Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Volume: 5 Issue: 4
Author(s): Albrecht Reichle
Affiliation:
Keywords: Tumor systems biology, systems assessment tools
Abstract: Background: A tumor system not only consists of diverse cell types but also comprises all components of action insofar that these components are oriented in terms of diverse cell types. Methods: Thus, it is necessary to decode paradox situations of cellular rationalization, deformation, and communication processes or, in other words, to uncover inconsistencies within tumor cell compartments or distinct topologies of aggregated action effects. Here, a theory may be helpful that discharges into an action-theoretical abstraction and simultaneously includes evolutionary tumor developments. In an evolutionary process, tumor cells may exploit the whole extent of the rationalization features of stroma cells to implement the functional diversity of systems behavior aimed at maintaining homeostasis, and robustness in tumor systems. The introduction of genomic/non-genomic systems-directed therapeutic approaches may allow both, the uncovering of systems topologies of aggregated action effects and the broadening of therapeutic options via systems-directed approaches. Results: (1) Tumor systems biology is now turning into a scientific co-subject. (2) Developing actiontheoretical systems terms with the corresponding conceptual equipment may contribute to the classification of tumor subsystems. (3) Systems-directed therapies may meet new therapeutic requirements, which might help to create therapeutic approaches that are specifically designed for the demand of tumor stages, corresponding systems stages. Conclusions: Therefore, patients would probably not have to be selected according to age and/or co-morbidities because of known adverse toxicities of standard therapies (maximal tolerable doses). In contrast, therapies may meet the (individual) tumor systems characteristics by a systems-orientated selection of biomodulatory acting agents. As shown, toxicities may be modest.
Export Options
About this article
Cite this article as:
Reichle Albrecht, Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options, Current Cancer Therapy Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339409789712690
DOI https://dx.doi.org/10.2174/157339409789712690 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Management of Unusual Not Scar Ectopic Pregnancy: A Multicentre Retrospective Case Series
Current Women`s Health Reviews The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets Asafoetida, Natural Medicine for Future
Current Nutrition & Food Science Inhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
Current Topics in Medicinal Chemistry Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Aqueous Extracts of Selected Potentilla Species Modulate Biological Activity of Human Normal Colon Cells
Current Drug Targets Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Anti-adipogenic and Cytotoxic Effects of a New Compound from <i>Hartmannia rosea</i> G. Don
Current Pharmaceutical Analysis Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Betulinic Acid and Brosimine B Hybrid Derivatives as Potential Agents against Female Cancers
Anti-Cancer Agents in Medicinal Chemistry Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis
Reviews on Recent Clinical Trials Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology